10-Q: Cardio Diagnostics Holdings Reports Third Quarter 2024 Results Amidst Regulatory Changes and Financial Challenges

Cardio Diagnostics Holdings reported a net loss of $1.4 million for the third quarter of 2024, alongside increased revenue and ongoing efforts to navigate regulatory changes and financial constraints.

Summary

• Cardio Diagnostics Holdings, Inc. reported a net loss of $1,412,566 for the three months ended September 30, 2024, compared to a net loss of $1,932,382 for the same period in 2023.
• The company's revenue for the third quarter of 2024 was $6,580, a decrease from $10,030 in the third quarter of 2023.
• For the nine months ended September 30, 2024, the net loss was $6,864,145, compared to $6,987,905 for the same period in 2023.
• Revenue for the first nine months of 2024 was $30,378, an increase from $11,755 in the same period of 2023.
• The company's operating expenses totaled $1,415,547 for the third quarter of 2024 and $6,879,853 for the first nine months of 2024.
• The company is facing challenges related to the FDA's new rule for laboratory developed tests (LDTs), which may require premarket authorization for their tests.
• The company's cash balance increased to $1,982,590 as of September 30, 2024, from $1,283,523 at the end of 2023.
• The company has an accumulated deficit of $21,232,525 as of September 30, 2024.
• The company has raised capital through the sale of common stock and warrants, and is exploring additional financing options.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive developments, such as increased revenue for the first nine months and a slightly improved net loss, the company faces significant challenges, including ongoing losses, regulatory hurdles, and the risk of delisting. The need for additional capital raises and the ineffective disclosure controls also contribute to a negative sentiment.

Positives

• The company's net loss decreased in both the third quarter and the first nine months of 2024 compared to the same periods in 2023.
• Revenue increased significantly in the first nine months of 2024 compared to the same period in 2023.
• The company's cash balance increased by approximately $700,000 as of September 30, 2024.
• The company has expanded the availability of its Epi+Gen CHD test to Family Medicine Specialists retail clinical locations.
• The company has received preliminary Medicare pricing for its PrecisionCHD and Epi+Gen CHD tests.

Negatives

• The company continues to operate at a loss, with a net loss of $1.4 million for the third quarter of 2024 and $6.8 million for the first nine months of 2024.
• Revenue for the third quarter of 2024 decreased compared to the same period in 2023.
• The company has an accumulated deficit of $21.2 million as of September 30, 2024.
• The company's disclosure controls and procedures are not effective.
• The company is facing challenges related to the FDA's new rule for laboratory developed tests (LDTs), which may require premarket authorization for their tests.

Risks

• The company's ability to continue as a going concern is dependent on obtaining necessary equity financing and generating revenues.
• The company is subject to the FDA's new rule for laboratory developed tests (LDTs), which may require premarket authorization for their tests, leading to increased costs and regulatory burdens.
• The company's common stock is at risk of being delisted from Nasdaq due to the bid price falling below the minimum $1.00 per share requirement.
• The company is involved in potential legal claims and disputes, which could require significant time and resources to defend and/or settle.
• The company's stock price is volatile, making it challenging to raise capital without significant dilution.
• The company's internal control over financial reporting is not effective.

Future Outlook

The company expects that working capital requirements will continue to be funded through a combination of its existing funds and further issuances of securities. The company anticipates that its principal sources of liquidity will only be sufficient to fund its activities over the next 12 months. The company will need to raise additional funds through the issuance of equity or convertible debt to fund operations beyond the next 12 months.

Management Comments

• The company aspires to give every American adult insight into their unique risk for various cardiovascular diseases.
• Cardio aims to become one of the leading medical technology companies for enabling improved prevention, early detection and treatment of cardiovascular disease.
• Cardio is transforming the approach to cardiovascular disease from reactive to proactive and hope to accelerate the adoption of Precision Medicine for all.
• The company believes that incorporating Cardio's solutions into routine practice in primary care and prevention efforts can help alter the trajectory that nearly one in two Americans is expected to develop some form of cardiovascular disease by 2035.

Industry Context

The company operates in the medical technology sector, specifically focusing on cardiovascular disease diagnostics. The company is navigating the evolving regulatory landscape for laboratory developed tests (LDTs), which is a significant trend in the industry. The company is also working to expand its market reach and adoption of its products across various healthcare verticals.

Comparison to Industry Standards

• The company's revenue is low compared to established diagnostic companies, reflecting its early stage of commercialization.
• The company's net losses are typical for early-stage biotech companies focused on research and development.
• The company's reliance on equity financing is common for companies in this sector, but the current stock price volatility presents a challenge.
• The company's efforts to obtain CPT PLA codes and Medicare pricing are important steps for reimbursement and market adoption, similar to other diagnostic companies.
• The company's focus on epigenetics and AI-driven diagnostics is a differentiating factor compared to traditional diagnostic companies.

Legal Proceedings

• The company is involved in potential legal claims and disputes related to prior relationships with Boustead Securities, LLC and The Benchmark Company, LLC.
• The company is also facing a potential mootness fee claim related to a demand letter from a plaintiffs securities law firm.
• The company is also facing a potential claim from Northland Securities, Inc.

Stakeholder Impact

• Shareholders face the risk of dilution from additional equity issuances and potential loss of investment if the company is unable to continue as a going concern.
• Employees may be impacted by the company's financial challenges and potential restructuring.
• Customers may be affected by the company's ability to continue providing its diagnostic services.
• Suppliers and creditors may be impacted by the company's financial instability.

Next Steps

• The company will continue to develop additional products, including clinical tests for stroke, congestive heart failure and diabetes.
• The company will expand its clinical and health economics evidence portfolio to continue to demonstrate value of products and increase reach.
• The company will leverage its newly-awarded CPT PLA codes.
• The company will expand the adoption of its products across key channels, including health systems and self-insured employers.
• The company will scale its internal operations capabilities with a focus on improving efficiency and reducing its cost of goods sold.
• The company will pursue potential strategic partnership(s) and acquisition(s) of one or more synergistic companies.
• The company will seek an extension from Nasdaq to regain compliance with the minimum bid price requirement.
• The company will continue to explore financing options to fund its operations.

Key Dates

Keywords

Cardiovascular disease, Epigenetics, Genetics, Laboratory developed tests, FDA regulation, Precision medicine, Financial results, Net loss, Revenue, Stock offering, Warrants, Nasdaq listing, Going concern